Sandy Spring Bank Decreases Stake in Shire PLC (SHPG)

Sandy Spring Bank Decreases Stake in Shire PLC (SHPG)

A number of other hedge funds also recently added to or reduced their stakes in SHPG. Dumont & Blake Investment Advisors LLC raised its stake in Shire PLC by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 2,594 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 7 shares during the last quarter. Bienville Capital Management LLC raised its stake in Shire PLC by 0.4% in the fourth quarter. Bienville Capital Management LLC now owns 2,453 shares of the biopharmaceutical company’s stock worth $418,000 after buying an additional 9 shares during the last quarter. Covington Capital Management raised its stake in Shire PLC by 1.1% in the third quarter. Covington Capital Management now owns 1,241 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 14 shares during the last quarter. Thompson Davis & CO. Inc. raised its stake in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares during the last quarter. Finally, HighPoint Advisor Group LLC raised its stake in Shire PLC by 2.2% in the third quarter. HighPoint Advisor Group LLC now owns 1,300 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 28 shares during the last quarter. Institutional investors own 22.69% of the company’s stock.

Sandy Spring Bank lowered its stake in shares of Shire PLC (NASDAQ:SHPG) by 19.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,203 shares of the biopharmaceutical company’s stock after selling 1,479 shares during the period. Sandy Spring Bank’s holdings in Shire PLC were worth $1,086,000 as of its most recent filing with the SEC.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.22 by $0.41. The firm had revenue of $3.57 billion for the quarter. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. Shire PLC’s quarterly revenue was up 109.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.12 EPS.

A number of research firms have weighed in on SHPG. Jefferies Group LLC set a $239.00 target price on Shire PLC and gave the stock a “buy” rating in a research note on Saturday, March 18th. HSBC Holdings plc lowered Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Guggenheim reiterated a “neutral” rating on shares of Shire PLC in a research note on Friday, February 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $221.00 target price on shares of Shire PLC in a research note on Tuesday, April 18th. Finally, Liberum Capital began coverage on Shire PLC in a research note on Thursday, March 9th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $210.89.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:SHPG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Related posts

Leave a Comment